Neogen (NEOG) Q1 Earnings Lag Estimates

Core Insights - Neogen (NEOG) reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share, and down from $0.07 per share a year ago, representing an earnings surprise of -20.00% [1] - The company posted revenues of $209.19 million for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 2.96%, but down from $216.96 million year-over-year [2] - Neogen shares have declined approximately 52.1% year-to-date, contrasting with the S&P 500's gain of 14.8% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Neogen was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Current consensus EPS estimate for the next quarter is $0.08 on revenues of $210.41 million, and $0.32 on revenues of $818.26 million for the current fiscal year [7] Industry Context - The Medical - Products industry, to which Neogen belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, ResMed (RMD), is expected to report quarterly earnings of $2.49 per share, reflecting a year-over-year increase of +13.2%, with revenues projected at $1.32 billion, up 7.9% from the previous year [9]